BDBM224221 5-{6-(5- chloropyridin-3-yl)- 8-[(2r,3r)-2,3- dimethylmorpholin- 4-yl]-7-[(trans-4- methylcyclohexyl) methyl]-7h-purin-2-yl}- 1,3,4-oxadiazol- 2(3h)-one::US9540377, 16.140

SMILES C[C@@H]1[C@@H](C)OCCN1c1nc2nc(-c3n[nH]c(=O)o3)nc(-c3cncc(Cl)c3)c2n1C[C@H]1CC[C@H](C)CC1

InChI Key InChIKey=VOXJMEPEQFUQDQ-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 224221   

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandChemical structure of BindingDB Monomer ID 224221BDBM224221(US9540377, 16.140 | 5-{6-(5- chloropyridin-3-yl)- ...)
Affinity DataIC50: 9.45nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2018
Entry Details
US Patent